Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a price target of $17.
August 26, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Reviva Pharmaceuticals, maintaining a $17 price target. This suggests confidence in the company's potential growth.
The reiteration of a Speculative Buy rating and maintenance of a $17 price target by a reputable analyst can boost investor confidence, potentially leading to a positive short-term impact on RVPH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100